| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.56▲ | 1.54▲ | 1.55▲ | 1.60▼ | 1.52▲ |
| MA10 | 1.55▲ | 1.55▲ | 1.57▼ | 1.59▼ | 1.56▼ |
| MA20 | 1.56▲ | 1.58▼ | 1.59▼ | 1.55▼ | 1.65▼ |
| MA50 | 1.58▼ | 1.58▼ | 1.58▼ | 1.59▼ | 2.08▼ |
| MA100 | 1.58▼ | 1.58▼ | 1.55▲ | 1.68▼ | 1.94▼ |
| MA200 | 1.59▼ | 1.55▲ | 1.57▼ | 1.91▼ | 3.08▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.002▲ | -0.004▼ | -0.007▼ | 0.007▲ | 0.004▲ |
| RSI | 47.652▼ | 47.318▼ | 47.078▼ | 46.835▼ | 43.520▼ |
| STOCH | 71.481 | 20.365 | 15.508▼ | 57.458 | 28.092 |
| WILL %R | -20.000▲ | -63.636 | -63.636 | -53.488 | -64.912 |
| CCI | 17.373 | -26.667 | -56.698 | 7.850 | -55.020 |
|
Friday, November 14, 2025 01:15 PM
“During our third quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/11/25 | 1.57 | 1.63 | 1.52 | 1.53 | 76,766 |
| 13/11/25 | 1.59 | 1.62 | 1.57 | 1.60 | 39,024 |
| 12/11/25 | 1.64 | 1.67 | 1.55 | 1.62 | 114,950 |
| 11/11/25 | 1.59 | 1.66 | 1.59 | 1.64 | 34,992 |
| 10/11/25 | 1.51 | 1.6745 | 1.51 | 1.59 | 146,898 |
| 07/11/25 | 1.47 | 1.5145 | 1.39 | 1.50 | 76,879 |
| 06/11/25 | 1.69 | 1.69 | 1.49 | 1.49 | 117,517 |
| 05/11/25 | 1.60 | 1.72 | 1.5803 | 1.70 | 210,883 |
| 04/11/25 | 1.62 | 1.70 | 1.5406 | 1.59 | 200,972 |
| 03/11/25 | 1.46 | 1.76 | 1.33 | 1.60 | 320,922 |
|
|
||||
|
|
||||
|
|